Ziopharm Oncology has reported the publication of an abstract on ZIO-201, a stabilized form of isophosphoramide mustard (IPM). The preclinical abstract is published and available online in Blood, the journal of the American Society of Hematology.
In the abstract, data regarding effects on rabbit kidney proximal tubule cells report ZIO-201 avoids kidney damage caused by metabolites of ifosfamide, the prodrug of ZIO-201. ZIO-201 is currently in a Phase I clinical trial in advanced cancers. The maximum tolerated dose is not yet identified.